CN116370476A - Chemotherapy medicine composition and application thereof - Google Patents
Chemotherapy medicine composition and application thereof Download PDFInfo
- Publication number
- CN116370476A CN116370476A CN202310436293.7A CN202310436293A CN116370476A CN 116370476 A CN116370476 A CN 116370476A CN 202310436293 A CN202310436293 A CN 202310436293A CN 116370476 A CN116370476 A CN 116370476A
- Authority
- CN
- China
- Prior art keywords
- ceritinib
- pharmaceutical composition
- drug
- effect
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title abstract description 54
- 239000000203 mixture Substances 0.000 title abstract description 13
- 238000002512 chemotherapy Methods 0.000 title abstract description 8
- QBIYUDDJPRGKNJ-UHFFFAOYSA-M sepantronium bromide Chemical compound [Br-].O=C1C2=CC=CC=C2C(=O)C2=C1N(CCOC)C(C)=[N+]2CC1=CN=CC=N1 QBIYUDDJPRGKNJ-UHFFFAOYSA-M 0.000 claims abstract description 101
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims abstract description 91
- 229960001602 ceritinib Drugs 0.000 claims abstract description 87
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 21
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 21
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 18
- 239000000890 drug combination Substances 0.000 claims description 6
- 238000011065 in-situ storage Methods 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 56
- 230000000694 effects Effects 0.000 abstract description 44
- 229940079593 drug Drugs 0.000 abstract description 30
- 238000011282 treatment Methods 0.000 abstract description 24
- 210000004881 tumor cell Anatomy 0.000 abstract description 19
- 230000005764 inhibitory process Effects 0.000 abstract description 14
- 206010067484 Adverse reaction Diseases 0.000 abstract description 9
- 206010059866 Drug resistance Diseases 0.000 abstract description 9
- 230000006838 adverse reaction Effects 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 9
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 5
- 238000011866 long-term treatment Methods 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 5
- -1 on one hand Chemical compound 0.000 abstract description 2
- 238000011580 nude mouse model Methods 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 18
- 241000699660 Mus musculus Species 0.000 description 17
- 229940090044 injection Drugs 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 206010006187 Breast cancer Diseases 0.000 description 13
- 208000026310 Breast neoplasm Diseases 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- 238000012795 verification Methods 0.000 description 10
- 230000037396 body weight Effects 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 229940093181 glucose injection Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 229940096116 Survivin inhibitor Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000009982 effect on human Effects 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000010304 tumor cell viability Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of chemotherapeutic drugs, and discloses a chemotherapeutic drug composition and application thereof, wherein the active ingredients of the drug composition comprise YM155 and ceritinib, and the mass ratio of the YM155 to the ceritinib is 4:2.025. according to the scheme, by combining YM155 and ceritinib, on one hand, YM155 cooperates with the inhibition effect of ceritinib on tumor cells, so that the treatment effect of chemotherapy is improved; on the other hand, YM155 can also obviously reduce the situation that the critinib inevitably kills normal cells to generate adverse reaction, reduce the drug resistance of tumor cells to the critinib in the long-term treatment process, and promote the treatment effect when the medicine is taken for a long time.
Description
Technical Field
The invention relates to the technical field of chemotherapeutic drugs, in particular to a chemotherapeutic drug composition and application thereof.
Background
Chemotherapy is one of the main methods for treating triple negative breast cancer, and is a treatment mode for preventing proliferation, infiltration and metastasis of triple negative breast cancer cells by using chemical medicines until the triple negative breast cancer cells are finally killed. However, some clinical first-line chemotherapeutics commonly used at present inevitably damage normal cells of human body while killing triple negative breast cancer cells due to weak selectivity, so that adverse reactions of the medicines occur. And the time for treating the triple negative breast cancer is relatively long, and drug resistance or drug resistance is easy to generate in the long-time treatment process.
How to improve the curative effect, reduce adverse drug reactions and prevent drug resistance on the premise of not damaging normal cells of a human body is a difficult point to overcome when a chemotherapeutic drug is used for treating cancers.
Disclosure of Invention
The invention aims to provide a chemotherapeutic medicine composition and application thereof, so as to solve the technical problems of limited treatment effect and serious adverse reaction caused by weak selectivity in the existing chemotherapeutic technology for treating triple negative breast cancer.
In order to achieve the above purpose, the invention adopts the following technical scheme: a chemotherapeutic pharmaceutical composition, the active ingredients of which comprise YM155 and ceritinib.
The principle and the advantages of the scheme are as follows: ceritinib (Cer, cas: 1032900-25-6) is used to treat metastatic non-small cell lung cancer (NSCLC) patients who are positive for Anaplastic Lymphoma Kinase (ALK), have a progressive tumor condition, or are intolerant to Crizotinib. YM155 (Sepantronium Bromide) (Survivin inhibitor) is a potent Survivin inhibitor that acts by inhibiting Survivin promoter activity and is effective in inhibiting human cancer cell lines (mutant p53 or short p 53). However, the killing effect of YM155 on tumor cells appears to be concentration dependent. In order to reduce the dosage of the medicine and avoid the side effects, the inventor combines the two medicines on the premise that the medicines are used singly and have no cytotoxicity to normal cells and tumor cells; the inventor experiment finds that the combination of the two medicines with low dosage can effectively inhibit the proliferation of tumor cells and induce the apoptosis of the tumor cells, and has unexpected technical effects.
Compared with the fact that the inhibition effect is limited when the two are used independently, the YM155 and the ceritinib are used in combination, the synergistic effect can be achieved, the inhibition effect of the ceritinib is improved, and the effect of inhibiting and killing triple negative breast cancer cells is improved. The inventor experiment shows that when the pharmaceutical composition of the scheme is used for inhibiting breast cancer MDA-MB-231 cells, MCF-7 cells and BT549 cells, under the condition of using YM155, the effects of inhibiting and killing the tumor cells are greatly improved, and the effect of YM155 combined with the ceritinib is obviously superior to the effect of single use of the two, and the effects have a synergistic effect.
In addition, the scheme can obviously reduce the situation that the critinib inevitably kills normal cells to generate adverse reaction by combining YM155 with the critinib, can reduce the drug resistance of tumor cells to the critinib in the long-term treatment process, and improves the inhibition effect of long-term treatment.
Preferably, the mass ratio of the YM155 to the ceritinib is 4:2.025 to 3.24.
The beneficial effects are that: the YM155 and the ceritinib with the mass ratio can effectively inhibit the formation of tumor cells, and have unexpected technical effects. The inventors have found experimentally that when a tumor is treated with a combination of YM155 and ceritinib, the minimum mass ratio of the actual dosage of YM155 to the actual dosage of ceritinib is 0.4mg to 0.2025mg; under the synergistic effect of the two, the dosage of the two medicines can be effectively reduced, the cost is reduced, and the adverse reaction of patients to ceritinib and the treatment risk of drug resistance can be reduced. The inventor experiment finds that if the mass ratio is higher than the mass ratio (for example, 4:1.5 is selected), the ideal inhibition effect cannot be achieved; if the mass ratio is lower than this, the normal cells of the patient are inevitably affected, which causes adverse reactions and adversely damages the health of the patient.
Preferably, the active ingredient is present in free form in molecular or ionic state.
The beneficial effects are that: in the scheme, before using YM155 and ceritinib, physiological saline or 5% glucose injection is needed to prepare YM155 into YM155 injection or ceritinib into ceritinib solution, so that the YM155 and the ceritinib are dissolved in the solution, and the dispersion is facilitated, and the drug effect is fully exerted.
The scheme also provides application of the chemotherapeutic medicine composition in preparing an anti-tumor medicine, wherein the tumor aimed by the anti-tumor medicine is in-situ or recurrent triple negative breast cancer.
The beneficial effects are that: the anti-tumor medicine is prepared from a chemotherapeutic medicine composition, the chemotherapeutic medicine composition consists of YM155 and ceritinib, and the YM155 and the ceritinib are combined to have remarkable inhibition effect on human triple negative breast cancer cells MDA-MB-231 and BT549 cells, and have weaker sensitization effect on non-triple negative breast cancer cells MCF-7 cells, so that the YM155 and the ceritinib can be used for treating triple negative breast cancer. The combination of YM155 and ceritinib showed good triple negative breast cancer cell inhibition. Triple negative breast cancer refers to breast cancer with negative Estrogen Receptor (ER), progestogen Receptor (PR) and protooncogene Her-2 as cancer tissue immunohistochemical examination results, and has the disadvantages of poor prognosis and high death risk.
Preferably, the active ingredients of the pharmaceutical composition include YM155 and ceritinib.
The beneficial effects are that: according to the scheme, by combining YM155 and ceritinib, on one hand, YM155 cooperates with the inhibition effect of ceritinib on tumor cells, so that the treatment effect of chemotherapy is improved; on the other hand, YM155 can also obviously reduce the situation that the critinib inevitably kills normal cells to generate adverse reaction, reduce the drug resistance of tumor cells to the critinib in the long-term treatment process, and promote the treatment effect when the medicine is taken for a long time.
Preferably, the pharmaceutical composition is administered intravenously.
The beneficial effects are that: the scheme adopts the administration mode, which not only accords with the traditional administration habit, but also is more convenient. Intravenous administration is a conventional mode of administration of YM155 and ceritinib. The injection of the ceritinib in the combination drug of the invention is a discontinuous administration mode which is the same as that of the single-use ceritinib injection. Because the medicine ceritinib has longer metabolism time in human body, the discontinuous medication mode can reduce toxic and side effects. Even though the YM155 is used cooperatively to form the pharmaceutical composition, the dosage of some ceritinib can be reduced, the administration mode is still adopted, and the traditional administration habit is met. When the medicine combination of the invention is applied, the step of injecting YM155 injection is only added, and no other special operation method is adopted, thus being more convenient. The actual amount of YM155 in the pharmaceutical composition of the present invention is far less than that of retinib. Experiments prove that the YM155 synergistic critinib can not only inhibit and kill various malignant tumor cells, but also reduce the dosage, shorten the treatment period and reduce the occurrence of toxic and side effects. Even in reverse, under the action of the prior clinical chemotherapeutic medicine ceritinib medium, the inventor of the application discovers that the YM155 has the effect of effectively inducing autophagy of various tumor cells and has the effect of killing various malignant tumor cells with reliable effect and practical value. .
Preferably, the YM155 is used in an amount of 0.4 mg/kg.bw.
Preferably, the dose of the ceritinib is 0.675-0.81 mg/kg.bw.
The beneficial effects are that: the inventor obtains single dose of YM155 and ceritinib by converting the result through animal experiments. In Experimental example 2, the single dose of YM155 was 5 mg/kg.bw, and the single dose of ceritinib was 10 mg/kg.bw. The conversion basis is given by the U.S. Food and Drug Administration (FDA) in the "estimate of safe dosing of healthy adult subjects in drug clinical trials" (Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers), the conversion ratio of the injected dose to the human and mouse (i.e., nude mice in experimental verification) required to achieve the same biological effect (1:12.3).
Preferably, the YM155 and ceritinib are administered at a frequency ratio of 10:3.
the beneficial effects are that: the scheme adopts the administration frequency, the use of the low-toxicity YM155 can reduce the administration times and dosage of the ceritinib, the adverse reaction and drug resistance caused by the administration are reduced while the inhibition effect is improved, and the inhibition effect of the ceritinib in the long-term treatment process is improved.
Drawings
FIG. 1 shows the inhibition curves of the combination of ceritinib single and ceritinib with YM155 (the subject is breast cancer cells, and the concentration of YM155 is constant) of experimental example 1.
FIG. 2 shows the cancer cell inhibition curves of YM155 alone and YM155 in combination with ceritinib of Experimental example 1 (the subjects were breast cancer cells, and the concentration of ceritinib was constant).
FIG. 3 is a graph showing tumor volumes of experimental mice after 21 days of treatment in experimental example 2.
FIG. 4 is a graph showing the change in body weight of the experimental mice of experimental example 2.
Fig. 5 is a graph showing the change in survival rate of experimental mice of experimental example 2.
Detailed Description
Example 1
A chemotherapeutic medicine composition of the scheme consists of active ingredients YM155 and ceritinib, wherein the structural formula of YM155 is shown in a formula (I), and the structural formula of ceritinib is shown in a formula (II).
When it is known that the pharmaceutical composition provided by the present invention can improve the curative effect and reduce adverse reactions, and the pharmaceutical composition of the present invention is adopted to avoid drug resistance or drug tolerance, it is fully possible for those skilled in the art to determine the ratio between the two components of YM155 and ceritinib by routine experiments of the system for specific malignant tumors. For a plurality of malignant tumor cells selected during experimental verification of the invention, the pharmaceutical composition is preferably prepared by adopting the proportion, and the mass ratio of the total drug quantity of YM155 to the total drug quantity of the ceritinib is 4 mg:2.025-2.43 mg in one treatment course (10 days). The dose ratio was converted based on the animal experimental dose (experimental example 2). The conversion basis is given by the U.S. Food and Drug Administration (FDA) in the "estimate of safe dosing of healthy adult subjects in drug clinical trials" (Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers), the conversion ratio of the injected dose to the human and mouse (i.e., nude mice in experimental verification) required to achieve the same biological effect (1:12.3).
The active ingredient in this embodiment is present in free form or in the form of a pharmaceutically acceptable salt. Specifically, before using YM155 and ceritinib in this solution, YM155 needs to be prepared into YM155 injection or ceritinib needs to be prepared into ceritinib solution by using normal saline or 5% glucose injection, so that the YM155 and the ceritinib are dissolved in the solution, which is helpful for dispersion and full play of drug effect.
The scheme also provides application of the chemotherapeutic medicine composition in preparing an anti-tumor medicine, wherein active ingredients of the medicine composition comprise YM155 and ceritinib, and tumors targeted by the anti-tumor medicine are in-situ or recurrent triple negative breast cancer. The drug combination is administrated intravenously; the dosage of YM155 was 0.4 mg/kg.bw, and the dosage of ceritinib was 0.81 mg/kg.bw; the dosing frequency ratio of YM155 and ceritinib was 10:3.
Specifically, when the pharmaceutical composition of the scheme is used for preparing an anti-tumor drug and treating in-situ or recurrent triple negative breast cancer, YM155 and ceritinib are uniformly and repeatedly administered (the ratio of total drug amount is kept to be 4mg: 2.025-2.43 mg, and the embodiment specifically takes 4mg:2.43mg as an example, the specific application method of the pharmaceutical composition of the scheme is as follows:
(1) YM155 was administered intravenously once daily at a dose of YM 155:patient weight=0.4 mg/kg (YM 155 was formulated as YM155 injection using physiological saline or 5% dextrose injection, in this example, physiological saline);
(2) on the same day as the YM155 injection according to step (1), the first time of the ceritinib injection was intravenously injected according to the dose of ceritinib: patient weight=0.81 mg/kg (the ceritinib injection is prepared by using physiological saline or 5% glucose injection, the glucose injection used in the present example);
(3) by the fifth day, the same dose of ceritinib injection is injected once again by vein according to the dose described in the step (2); cycling according to steps (1) - (3);
(4) from the tenth day, it is determined whether or not to cycle according to the methods of steps (1) to (3), and the number of cycles and the intermediate withdrawal time, according to the bearing capacity and the therapeutic effect of the patient's body.
It is clear to those skilled in the art that the concentration of the injection should be determined according to factors such as the bearing capacity of the patient's body, the number of "cycles" in step (4) may be generally 1 to 4 times, and the "intermediate withdrawal time" may be generally 1 to 2 weeks; for patients with particularly poor body condition, it is even possible to use steps (1) and (2) as a medication cycle or a treatment course (i.e. to pause the medication from day six).
Experimental example 1: cell experiment
1. Cell selection and active culture
The experiment selects human breast cancer cells MDA-MB-231, MCF-7 and BT549. Wherein, human breast cancer cells MDA-MB-231, MCF-7 and BT549 are cultured in DMEM+10% FBS complete culture medium, and the above cells are all at 37 ℃ and CO with 5% concentration 2 Culturing in a saturated humidity cell incubator.
2. Experimental methods and results
After each tumor cell line had stabilized, cells were plated in 96-well plates with 5000 cells per well, each containing 90 μl of complete medium, and then treated with drugs. MTT assay was performed on the treated cells to determine the effect of the drug on cell activity: after 48 hours of dosing, 20. Mu.L of a solution of 5mg/mL thiazole blue (MTT) in Phosphate Buffer (PBS) was added to each well and incubation was continued for 4 hours. The upper medium was aspirated, 150 μl of Dimethylsulfoxide (DMSO) was added to each well for solubilization, and after 10 minutes of solubilization on a shaker, absorbance values were measured at a495 with a microplate reader, and cell viability was calculated according to the following formula:
percent cell viability = (treatment group absorbance-blank well absorbance)/(control group absorbance-blank well absorbance) ×100%.
The specific experimental grouping mode is as follows:
human breast cancer cells MDA-MB-231, MCF-7, BT549 were grouped and treated as follows:
(1) Control group: treatment was performed with 10. Mu.L of the complete medium solution.
(2) Ceritinib group: the complete culture medium is used to prepare the ceritinib solution with the concentration of 0, 1, 2, 4, 6, 8 and 10 mu M (mu mol/L), and 10 mu L of treatment is added to each well to make the final concentration of the ceritinib solution be 0, 0.1, 0.2, 0.4, 0.6, 0.8 and 1.0 mu M. The experimental results are shown in fig. 1.
(3) YM155 group: YM155 solutions at concentrations of 0, 0.5, 1, 2, 4, 6, 8, 10, 20. Mu.M (. Mu.mol/L) were prepared with complete medium, and 10. Mu.L of treatment was added to each well to give final concentrations of 0, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 2.0. Mu.M. The experimental results are shown in fig. 2.
(4) Combination group: ceritinib and YM155 combined pharmaceutical group
The combination of ceritinib and YM155 used two experimental protocols:
scheme one: the complete culture medium was used to prepare 0, 1, 2, 4, 6, 8, 10. Mu.M of ceritinib solution and 20. Mu.M of YM155 mixed liquor, and 10. Mu.L of mixed liquor was added to each well to make the final concentration of ceritinib effect be 0, 0.1, 0.2, 0.4, 0.6, 0.8, 1. Mu.M and the final concentration of YM155 effect be 2. Mu.M, and the experimental results are shown in FIG. 1.
As can be seen from fig. 1, ceritinib itself has a certain concentration-dependent cancer cell inhibitory effect at a high dose, whereas the same concentration of ceritinib has an enhanced cancer cell inhibitory effect under the action of YM 155.
Scheme II: the YM155 solution with the concentration of 0, 0.5, 1, 2, 4, 6, 8, 10 and 20 mu M and the ceritinib mixed liquor with the concentration of 5 mu M are prepared by using a complete culture medium, 10 mu L of mixed liquor is added to each hole for treatment, so that the final working concentration of the YM155 is 0, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8, 1.0 and 2.0 mu M, and the final working concentration of the ceritinib is 0.5 mu M, and the experimental results are shown in figure 2.
As can be seen from fig. 2, YM155 itself does not have a significant cancer cell inhibitory effect, and as the amount of YM155 increases, YM155 does not exhibit a cancer cell inhibitory effect. However, after the addition of 0.5 μm of ceritinib, the composition has a remarkable effect of inhibiting cancer cells, which is not only produced by ceritinib alone, but is achieved by the synergistic effect of ceritinib and YM 155.
In combination with FIGS. 1 and 2, YM155 alone had no significant effect on cell viability. The tumor cell viability of the YM155 co-ceritinib group was lower to a different extent than that of the ceritinib group alone, the combined effects of the two are not added, but the effects of 1+1 is larger than 2, and the two are synergistic, so that the anti-cancer agent has unexpected technical effects on inhibiting cancer cells.
By combining the experimental results of fig. 1 and 2, the combined use of the YM155 and the ceritinib has remarkable inhibition effect on human triple negative breast cancer cells MDA-MB-231 and BT549 cells, and has weaker sensitization effect on non-triple negative breast cancer cells MCF-7 cells, so that the YM155 and the ceritinib can be used for treating triple negative breast cancer. The combination of YM155 and ceritinib showed good triple negative breast cancer cell inhibition.
In fig. 1 to 2, the ordinate indicates the cell viability, that is, the cell viability of the treatment group relative to the control group. The abscissa represents various human tumor cell lines (note: only represented by the distinguishing symbol of the corresponding tumor cells). The values corresponding to the columns are the average values of the groups, and the "I" symbols in the figures indicate the vertical deviations.
It is clear to those skilled in the art that in the cell experiments, the drug effect only corresponds to the drug concentration, not to the total amount of the drug, and at the same time, the drug concentration at the cell level cannot be converted from the concentration in the animal experiments, so that the cell level experiments can only verify that the drug combination of YM155 co-chromene has no significant difference compared with chromene alone. Of course, the effectiveness and reliability of the pharmaceutical combinations of the present invention are also well documented by this verification. When the effect of the medicine combination is further verified through a nude mouse experiment, only one tumor cell is researched.
Experimental example 2: nude mice transplantation tumor model experiment (taking transplantation of human breast cancer MDA-MB-231 cells as an example)
During this experiment, various drugs were injected intraperitoneally into nude mice for comparison (i.e., not intravenously). Thus, the dose was converted based on the injection dose conversion ratio (1:12.3) of human to mouse (i.e., nude mouse in experimental verification) required to achieve the same biological effect, as given by the U.S. Food and Drug Administration (FDA) in the "estimate of safe dose for healthy adult subject in drug clinical trial" (Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers).
1. Selection of nude mice
24 nude mice with 6-8 weeks age and no specific pathogenic microorganism (SPF) level are taken, the weight range is 20+/-2 g, and the nude mice are fed in a day-night alternate room temperature (20-23 ℃) environment and are free to drink and eat.
2. Experimental grouping and dosing (4 groups total)
All nude mice were randomly divided into four groups of 6, each inoculated with 1X 10 on the outside of the right thigh 7 The individual used 0.2mL of suspension prepared from human breast cancer MDA-MB-231 cells (the culture of human breast cancer MDA-MB-231 cells was the same as in the "cell experiment" described above), and administration was started after neoplasia as follows.
(1) Control group: the physiological saline with the same volume as the treatment group is injected into the abdominal cavity for 1 time/day;
(2) YM155 group: injecting YM155 into the abdominal cavity for 1 time/day according to the dosage of 5mg/kg of the body weight of the nude mice;
(3) Ceritinib group: injecting chromene intraperitoneally at a dose of 10mg/kg of nude mice body weight 2 times/5 days (i.e. 1 time at 3-day intervals);
(4) Drug combination group of YM155 and ceritinib: injecting YM155 into the abdominal cavity for 1 time/day according to the dosage of 5mg/kg of the body weight of the nude mice; on the same day as the first YM155 injection, ceritinib was injected intraperitoneally at a dose of 10mg/kg of nude mice body weight 1 time at 3-day intervals (the dosing frequency ratio of YM155 and ceritinib was 10:3).
The doses of YM155 and ceritinib in each of the above groups are only those of the drug itself. The concentration to be achieved when formulated into an injection should be clear to those skilled in the art and will not be described in detail.
3. Measurement and recording
(1) Body weight of each group of nude mice was measured and recorded once every 7 days later;
(2) Measuring the length and width of the tumor by using a vernier caliper after every 21 days, and recording the volume of the tumor body part of each group of nude mice once; tumor volume was calculated according to the following formula:
tumor volume (mm) 3) =tumor length (mm) ×square of tumor width (mm) 2 )
The experimental results are shown in fig. 3-5, and the ordinate in fig. 3 represents the tumor volume of each group of nude mice; the abscissa represents the grouping; the values at each point are the actual values of the tumor volumes of each group (the "I" symbol in the figure indicates the up-down deviation). The ordinate in fig. 4 represents the average body weight of each group of nude mice; the abscissa represents a measurement time point; various line nodes represent various treatment groups; the values for each point are the average body weights of the groups. The survival rate of each group of nude mice is shown on the ordinate in fig. 5; the abscissa represents a time node; various line nodes represent various treatment groups.
As can be seen from fig. 3, the tumor volume of the YM155 co-ceritinib group was significantly lower after 21 days of treatment than that of the group of ceritinib alone and YM155 alone. The same applies to fig. 3 where p < 0.01, and it is also assumed that the tumor volume of the group using YM155 co-chronicinib is less likely to be wrong than that of the drug alone and the control group, and the verification result is accurate and reliable.
As can be seen from fig. 4, the mice weight of YM155 co-critinib group was not significantly different from the other drug and control groups alone, compared to the critinib alone, the YM155 alone, and the control group. n.s represents p > 0.05, i.e. the probability of error occurrence due to the difference between the weight of the YM155 co-chromene group and the drug group or the control group alone is greater than 0.05, and since p=0.05 is the statistically acceptable maximum error probability, the error probability of greater than 0.05 is not recognized here, i.e. no significant difference is found.
The verification result recorded in fig. 5 proves that the drug combination of YM155 and the ceritinib chemotherapy is better than the ceritinib alone in inhibiting and killing human breast cancer MDA-MB-231 cells, so that the survival period of the mouse model is prolonged, the dosage can be naturally reduced, the treatment period is shortened, and the toxic and side effects are reduced. The same table in fig. 5 indicates that p < 0.01, and it is also recognized that the treatment effect using YM155 co-chromene group is less likely to be wrong than that of the drug group alone and the control group, and the verification result is also accurate and reliable.
As no obvious toxic or side effect is seen in the description of FIG. 4, the verification result proves that the YM155 is cooperated with the pharmaceutical combination of the ceritinib chemotherapy, and at least no obvious toxic or side effect exists as the ceritinib alone.
It is clear to those skilled in the art that after the verification of the above cell experiment, it can be fully demonstrated that the drug combination of YM155 synergistic critinib chemotherapy has better therapeutic effect on human breast cancer cells, especially triple negative breast cancer (differential and very small) through a nude mouse transplantation tumor model experiment on human breast cancer MDA-MB-231 cells.
The foregoing is merely exemplary of the present invention, and specific technical solutions and/or features that are well known in the art have not been described in detail herein. It should be noted that, for those skilled in the art, several variations and modifications can be made without departing from the technical solution of the present invention, and these should also be regarded as the protection scope of the present invention, which does not affect the effect of the implementation of the present invention and the practical applicability of the patent. The protection scope of the present application shall be subject to the content of the claims, and the description of the specific embodiments and the like in the specification can be used for explaining the content of the claims.
Claims (9)
1. A chemotherapeutic pharmaceutical composition, characterized in that: the active ingredients of the pharmaceutical composition include YM155 and ceritinib.
2. A chemotherapeutic pharmaceutical composition according to claim 1, wherein: the mass ratio of the YM155 to the ceritinib is 4:2.025 to 3.24.
3. The use of a chemotherapeutic pharmaceutical composition in the manufacture of an anti-neoplastic agent, characterized in that: the active ingredient is present in free form or in the form of a pharmaceutically acceptable salt.
4. Use of a chemotherapeutic pharmaceutical composition according to any one of claims 1 to 3 for the preparation of an antitumor drug, characterized in that: the tumor aimed by the anti-tumor drug is in-situ or recurrent triple negative breast cancer.
5. The use of a chemotherapeutic pharmaceutical composition according to claim 4, wherein: the active ingredients of the pharmaceutical composition include YM155 and ceritinib.
6. The use of a chemotherapeutic pharmaceutical composition according to claim 5, wherein: the drug combination is administrated intravenously.
7. The use of a chemotherapeutic pharmaceutical composition according to claim 6, wherein: the dosage of YM155 was 0.4 mg/kg.bw.
8. The use of a chemotherapeutic pharmaceutical composition according to claim 7, wherein: the dosage of the ceritinib is 0.675-0.81 mg/kg.bw.
9. The use of a chemotherapeutic pharmaceutical composition according to claim 8, wherein: the administration frequency ratio of YM155 to ceritinib is 10:3.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310436293.7A CN116370476B (en) | 2023-04-21 | 2023-04-21 | Chemotherapy medicine composition and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310436293.7A CN116370476B (en) | 2023-04-21 | 2023-04-21 | Chemotherapy medicine composition and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116370476A true CN116370476A (en) | 2023-07-04 |
CN116370476B CN116370476B (en) | 2024-01-30 |
Family
ID=86980707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310436293.7A Active CN116370476B (en) | 2023-04-21 | 2023-04-21 | Chemotherapy medicine composition and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116370476B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105294649A (en) * | 2014-07-30 | 2016-02-03 | 江苏奥赛康药业股份有限公司 | Ceritinib compound and pharmaceutical composition thereof |
US20170281624A1 (en) * | 2014-09-13 | 2017-10-05 | Novartis Ag | Combination therapies of alk inhibitors |
CN111544598A (en) * | 2020-05-12 | 2020-08-18 | 华东理工大学 | Ferritin nanoparticle loaded with Survivin double inhibitors as well as preparation method and application thereof |
CN113226318A (en) * | 2018-08-13 | 2021-08-06 | 北京智康博药肿瘤医学研究有限公司 | Biomarkers for cancer therapy |
-
2023
- 2023-04-21 CN CN202310436293.7A patent/CN116370476B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105294649A (en) * | 2014-07-30 | 2016-02-03 | 江苏奥赛康药业股份有限公司 | Ceritinib compound and pharmaceutical composition thereof |
US20170281624A1 (en) * | 2014-09-13 | 2017-10-05 | Novartis Ag | Combination therapies of alk inhibitors |
CN113226318A (en) * | 2018-08-13 | 2021-08-06 | 北京智康博药肿瘤医学研究有限公司 | Biomarkers for cancer therapy |
CN111544598A (en) * | 2020-05-12 | 2020-08-18 | 华东理工大学 | Ferritin nanoparticle loaded with Survivin double inhibitors as well as preparation method and application thereof |
Non-Patent Citations (2)
Title |
---|
ATIF ZAFAR: "Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope", CANCER LETTERS, vol. 496, pages 16 - 29, XP086350047, DOI: 10.1016/j.canlet.2020.09.023 * |
BAI-LING LUO: "MS-275 potentiates the effect of YM-155 in lung adenocarcinoma via survivin downregulation induced by miR-138 and miR-195", THORACIC CANCER, no. 10, pages 1355 - 1368 * |
Also Published As
Publication number | Publication date |
---|---|
CN116370476B (en) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112274525B (en) | Chemotherapy pharmaceutical composition and application thereof | |
CN108524533A (en) | A kind of compound is used as antitumor drug synergist and reversal agent | |
CN105476996A (en) | Application of curcumin and afatinib for combined treatment of non-small cell lung cancer | |
CN116370476B (en) | Chemotherapy medicine composition and application thereof | |
CN110496129B (en) | Anti-tumor activity of linagliptin and new application thereof | |
CN111228287A (en) | Application of epimedium flavone glycoside compound in preparing medicine for treating melanoma | |
CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
CN109793727A (en) | A kind of pharmaceutical composition and its application of effective anti-malignant tumor | |
KR102578970B1 (en) | Use of 2,3,5-Substituted Thiophene Compound for Prevention, Improvement or Treatment of Ovarian Cancer | |
CN111494385B (en) | Medicine for treating ovarian cancer and preparation method and application thereof | |
US20200375943A1 (en) | Cytocidal method of cancer cells selectively in human patients clinically by depletion of l-ascorbic acid, primarily, with its supplementation alternately augmenting its cytocidal effect | |
CN108992463B (en) | Composition and medicinal preparation for treating lung cancer | |
CN111558045A (en) | Medicine composition for treating lung cancer | |
CN113116914A (en) | Pharmaceutical composition with synergistic inhibition effect on proliferation of non-small cell lung cancer A549 cells and application thereof | |
CN105769884B (en) | A kind of pharmaceutical composition for treating lung cancer | |
CN105193810B (en) | 5 fluorouracil compositions and its application in antitumor injection is prepared | |
CN106668061B (en) | A kind of anticancer pharmaceutical composition containing cis-platinum | |
CN105055399A (en) | Natural product composition for preventing and treating diabetes and application thereof | |
CN1120002C (en) | Application of ammonium nilrate in pharmaceutical industry, food and health-care product | |
CN105769849B (en) | A kind of pharmaceutical composition for treating oophoroma | |
CN110876803B (en) | Pharmaceutical composition containing milk protein and oleic acid | |
CN111544580B (en) | Anti-cancer pharmaceutical composition | |
CN111840523B (en) | An anticancer pharmaceutical composition containing active protein and active fatty acid | |
CN113827604B (en) | Application of adefovir in preparing medicine for treating tumor or resisting tumor metastasis | |
CN111110851B (en) | Pharmaceutical composition of baicalein and tyrosine kinase inhibitor and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |